SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-23-000014
Filing Date
2023-01-20
Accepted
2023-01-20 08:07:57
Documents
12
Period of Report
2023-01-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20230113.htm   iXBRL 8-K 40540
  Complete submission text file 0001640455-23-000014.txt   179057

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20230113.xsd EX-101.SCH 1903
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20230113_lab.xml EX-101.LAB 24831
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20230113_pre.xml EX-101.PRE 13047
6 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20230113_htm.xml XML 10832
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 23538947
SIC: 2836 Biological Products, (No Diagnostic Substances)